Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | EYA2 | O00167 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | DRD1 | P21728 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6511739 | 1.00 | CYP2D6 (0.35) | CYP2D6TDP1EYA2APPACE | |
| SCHEMBL5032518 | 0.86 | TDP1 (0.31) | TDP1EYA2APPACEKDM4E | |
| SCHEMBL4564930 | 0.86 | TDP1 (0.31) | TDP1EYA2APPACEKDM4E | |
| SCHEMBL14345486 | 0.86 | TDP1 (0.31) | TDP1EYA2APPACEKDM4E | |
| SCHEMBL14439214 | 0.85 | — | — | |
| SCHEMBL12202789 | 0.82 | — | — | |
| SCHEMBL12202775 | 0.82 | — | — | |
| SCHEMBL8874144 | 0.81 | TDP1 (0.39) | TDP1EYA2APPACEKDM4E | |
| SCHEMBL3498361 | 0.81 | TDP1 (0.33) | TDP1EYA2APPACEKDM4E | |
| SCHEMBL12694735 | 0.80 | TDP1 (0.33) | TDP1EYA2APPACEKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7927581-B2 | For magnetic resonance imaging (MRI); peptide modified at its N- and its C-termini, independently, with a moiety comprising a metal chelate complex; specific binding affinity for fibrin; sufficient half-life in vivo | Factor 1A, LLC (US) | 2011-04-19 | — | — | US | disclosed |
| US-7871596-B2 | Higher fatty acid triester compound having diethylenetriamine-type metal chelate structure | FUJIFILM CORPORATION (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20080299043-A1 | having superior solubility anf miscibility with membrane components of liposomes; suitable for a liposome contrast medium selective for a lesion such as vascular diseases; chelate compound | FUJIFILM CORPORATION (JP) | 2008-12-04 | — | — | US | disclosed |
| US-7238341-B2 | Peptide-based multimeric targeted contrast agents | EPIX PHARMACEUTICALS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-20060039861-A1 | Peptide-based multimeric targeted contrast agents | EPIX MEDICAL, INC., A DELAWARE CORPORATION | 2006-02-23 | — | — | US | disclosed |
| US-20050074411-A1 | Peptide-based multimeric targeted contrast agents | EPIX MEDICAL, INC. A DELAWARE CORPORATION | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060039861-A1 | Peptide-based multimeric targeted contrast agents | NGLY1, IAPP, NPPA | CYP2D6 4872/4885TDP1 3429/4885EYA2 4040/4885 |
| US-20080299043-A1 | having superior solubility anf miscibility with membrane components of liposomes; suitable for a liposome contrast medium selective for a lesion such as vascular diseases; chelate compound | LIPA, APOB, MSR1 | CYP2D6 4692/4885TDP1 4742/4885EYA2 4448/4885 |
| US-20050074411-A1 | Peptide-based multimeric targeted contrast agents | NGLY1, IAPP, NPPA | CYP2D6 4872/4885TDP1 3429/4885EYA2 4040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.